Connection

Evangelos Terpos to Antibodies, Monoclonal

Back to Details
This is a "connection" page, showing publications Evangelos Terpos has written about Antibodies, Monoclonal.
Evangelos Terpos
Connection Strength
0.087
Antibodies, Monoclonal
  1. The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. Blood. 2018 01 25; 131(4):464-467.
    View in: PubMed
    Score: 0.045
  2. Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. Br J Haematol. 2017 Mar; 176(5):783-795.
    View in: PubMed
    Score: 0.042
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.